Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director · Chief Executive Officer | September 14, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date September 14, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 2,244,640 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 750,000 · Balance 2,244,640 F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 14, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389887 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,244,640 F1 · shares: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| September 03, 2026 Filed Sep 5, 2026 01:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 19,023 | $37.94 | $721,732.62 |
DisclosureSEC source: 0001193125-26-384042 · ownership.xml · nonDerivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,494,640 F3 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022 F4 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 5, 2026 01:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-384042 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,513,663 F1 · shares: The common shares represent the first tranche of performance share units granted effective February 3, 2026. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. F2 · balance_after: Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-345839 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,246 F1 · shares: The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 29,208 | $45.03 | $1,315,236.24 |
DisclosureSEC source: 0001193125-26-285562 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,098,246 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 13:45 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276882 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,127,454 F1 · shares: The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 22:42 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 24,431 | $18.47 | $451,240.57 |
DisclosureSEC source: 0001193125-26-126825 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 752,454 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:53 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 320,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039571 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,477 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 25,791 | $13.15 | $339,071.70 |
DisclosureSEC source: 0001193125-25-335483 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 778,477 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 21:35 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 25,797 | $9.77 | $252,036.69 |
DisclosureSEC source: 0001193125-25-220847 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 804,268 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 26,491 | $6.80 | $180,138.80 |
DisclosureSEC source: 0000950170-25-090428 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 830,065 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 21:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 21,208 | $6.74 | $142,941.92 |
DisclosureSEC source: 0000950170-25-045397 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 856,556 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-038801 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,764 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. F2 · balance_after: Amount includes 1,098 shares acquired under the Mind Medicine (MindMed) Inc. 2024 Employee Share Purchase Plan on February 18, 2025. Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 21:31 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 19,106 | $7.43 | $141,957.58 |
DisclosureSEC source: 0001104659-24-132167 · tm2432133-4_4seq1.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 526,666 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 00:29 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 19,771 | $5.98 | $118,230.58 |
DisclosureSEC source: 0000950170-24-109449 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 545,772 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 01:14 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | PurchaseCommon Shares | 500 | $6.12 | $3,060.00 |
DisclosureSEC source: 0000950170-24-099351 · ownership.xml · nonDerivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,543 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 01:14 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | PurchaseCommon Shares | 500 | $6.31 | $3,155.00 |
DisclosureSEC source: 0000950170-24-099351 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,043 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions on August 19, 2024, at prices ranging from $6.29 to $6.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2024 Filed Jun 25, 2024 23:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 15,659 | $7.22 | $113,057.98 |
DisclosureSEC source: 0000950170-24-077495 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,543 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 21:15 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 16,519 | $9.50 | $156,930.50 |
DisclosureSEC source: 0000950170-24-036572 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 580,202 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2024 at prices ranging from $9.37 to $9.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0000950170-24-023202 · ownership.xml · derivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2034-02-26 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:50 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 13,237 | $3.63 | $48,050.31 |
DisclosureSEC source: 0000950170-23-073069 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596,721 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2023 at prices ranging from $3.60 to $3.67 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 8,231 | $3.58 | $29,466.98 |
DisclosureSEC source: 0000950170-23-049779 · ownership.xml · nonDerivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,729 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $3.57 to $3.60 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 5,268 | $3.57 | $18,806.76 |
DisclosureSEC source: 0000950170-23-049779 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 619,960 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on September 25, 2023. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $4.78 to $4.84 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:41 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 8,416 | $3.21 | $27,015.36 |
DisclosureSEC source: 0000950170-23-030256 · ownership.xml · nonDerivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 623,457 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $3.20 to $3.23 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:41 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 7,086 | $3.19 | $22,604.34 |
DisclosureSEC source: 0000950170-23-030256 · ownership.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,873 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on June 27, 2023. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $4.20 to $4.23 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 22:41 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019896 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,959 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 02:43 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 8,273 | $3.51 | $29,038.23 |
DisclosureSEC source: 0000899243-23-006786 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,959 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on March 1, 2023. These shares were sold in multiple transactions on March 1, 2023 at prices ranging from $4.75 to $4.80 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:37 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,861 | $2.69 | $10,386.09 |
DisclosureSEC source: 0000899243-22-039214 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,232 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on November 15, 2022, November 24, 2022, and December 15, 2022, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on December 21, 2022. These shares were sold in multiple transactions on December 21, 2022 at prices ranging from $3.65 to $3.67 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 25, 2022 21:57 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,207 | $2.81 | $3,391.67 |
DisclosureSEC source: 0000899243-22-034146 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,093 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in multiple transactions, all at a price of $3.83 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 25, 2022. Read SEC document |
| October 18, 2022 Filed Oct 18, 2022 20:34 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,220 | $3.11 | $3,794.20 |
DisclosureSEC source: 0000899243-22-033749 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,300 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 15, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $4.28 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 18, 2022. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 22:39 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,264 | $5.51 | $6,964.64 |
DisclosureSEC source: 0000899243-22-032164 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,520 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $7.60 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 26, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 16:58 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,350 | $7.26 | $9,801.00 |
DisclosureSEC source: 0000899243-22-031430 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,784 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 15, 2022 pursuant to sell-to-cover elections F2 · price: The Common Shares were sold in one transaction at a price of $9.65 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 16, 2022. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 16:16 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,228 | $11.67 | $14,330.76 |
DisclosureSEC source: 0000899243-22-030156 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,134 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on August 24, 2022 pursuant to sell-to-cover elections F2 · price: The Common Shares were sold in one transaction at a price of $15.31 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 31, 2022. F3 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:36 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 20,350 | $0.68 | $13,838.00 |
DisclosureSEC source: 0000899243-22-029072 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,860,438 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on August 15, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.87 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 16, 2022. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 17:23 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 18,681 | $0.69 | $12,889.89 |
DisclosureSEC source: 0000899243-22-026724 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,880,788 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.88 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 25, 2022. Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 22:35 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 19,388 | $0.70 | $13,571.60 |
DisclosureSEC source: 0000899243-22-026255 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,899,469 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 15, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 18, 2022. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 22:05 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 36,762 | $0.70 | $25,733.40 |
DisclosureSEC source: 0000899243-22-024435 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,918,857 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on June 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 27, 2022. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:12 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 21,275 | $0.70 | $14,892.50 |
DisclosureSEC source: 0001209191-22-038480 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,955,619 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on June 15, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.91 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 16, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 01:09 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleSubordinate Voting Shares | 18,415 | $0.77 | $14,179.55 |
DisclosureSEC source: 0001209191-22-032383 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,976,894 F1 · kind: Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 24, 2022. F2 · price: The Subordinate Voting Shares were sold in one transaction at a price of $0.99 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 25, 2022. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:16 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleSubordinate Voting Shares | 18,948 | $0.71 | $13,453.08 |
DisclosureSEC source: 0001209191-22-030499 · doc4a.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,995,309 F1 · kind: Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 15, 2022. F2 · price: The Subordinate Voting Shares were sold in one transaction at a price of $0.92 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 18, 2022. Read SEC document |
| May 15, 2022 Filed May 18, 2022 01:34 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 18,948 | $0.82 | $15,537.36 |
DisclosureSEC source: 0001209191-22-029901 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,995,309 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,313 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of May 13, 2022 on the NEO was $1.00 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 23:18 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 19,110 | $0.92 | $17,581.20 |
DisclosureSEC source: 0001209191-22-024842 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,257 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of April 18, 2022 on the NEO was $1.16 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:03 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 2,910,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021385 · doc4.xml · derivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,425,500 Underlying: Subordinate Voting Shares · 2,910,000 shares Expires 2027-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:03 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 1,820,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021385 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033,367 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:26 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 12,612 | $1.00 | $12,612.00 |
DisclosureSEC source: 0001209191-22-019815 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213,367 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of March 15, 2022 on the NEO was $1.28 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 02:16 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 18,734 | $1.35 | $25,290.90 |
DisclosureSEC source: 0001209191-22-011077 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225,979 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,313 restricted stock units. Read SEC document |
| January 15, 2022 Filed Jan 20, 2022 00:14 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 190,287 | $1.05 | $199,801.35 |
DisclosureSEC source: 0001209191-22-003854 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,713 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 608,750 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.